Alterity Therapeutics's Enterprise Value for the quarter that ended in Sep. 2023 was $0.00 Mil.
Alterity Therapeutics's EBIT for the trailing twelve months (TTM) ended in Sep. 2023 was $0.00 Mil. Alterity Therapeutics's Earnings Yield (Joel Greenblatt) for the quarter that ended in Sep. 2023 was 0.00%.
The historical rank and industry rank for Alterity Therapeutics's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:
ATHE'
s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: -17325.43 Med: 51.94 Max: 316.36
Current: -51.02
During the past 13 years, the highest Earnings Yield (Joel Greenblatt) of Alterity Therapeutics was 316.36%. The lowest was -17325.43%. And the median was 51.94%.
ATHE's Earnings Yield (Joel Greenblatt) % is ranked worse than 87.34% of 1398
companies
in the Biotechnology industry
Industry Median: -15.175
vs ATHE: -51.02
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. Alterity Therapeutics's Forward Rate of Return (Yacktman) % for the quarter that ended in Sep. 2023 was 0.00%. The Forward Rate of Return uses the normalized Free Cash Flow of the past seven years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.
Alterity Therapeutics Earnings Yield (Joel Greenblatt) % Historical Data
The historical data trend for Alterity Therapeutics's Earnings Yield (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Alterity Therapeutics Annual Data
Trend
Jun14
Jun15
Jun16
Jun17
Jun18
Jun19
Jun20
Jun21
Jun22
Jun23
Earnings Yield (Joel Greenblatt) %
-108.70
-116.28
-48.54
454.55
-909.09
Alterity Therapeutics Quarterly Data
Dec17
Jun18
Dec18
Jun19
Sep19
Dec19
Jun20
Dec20
Mar21
Jun21
Sep21
Dec21
Mar22
Jun22
Sep22
Dec22
Mar23
Jun23
Sep23
Dec23
Earnings Yield (Joel Greenblatt) %
-
-
-909.09
-
-
Competitive Comparison
For the Biotechnology subindustry, Alterity Therapeutics's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alterity Therapeutics Earnings Yield (Joel Greenblatt) % Distribution
For the Biotechnology industry and Healthcare sector, Alterity Therapeutics's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Alterity Therapeutics's Earnings Yield (Joel Greenblatt) % falls into.
In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.
Alterity Therapeuticss Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Jun. 2023 is calculated as
Alterity Therapeutics's EBIT for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.
Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.
Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.
Be Aware
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
Alterity Therapeutics Earnings Yield (Joel Greenblatt) % Related Terms
Thank you for viewing the detailed overview of Alterity Therapeutics's Earnings Yield (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.
Alterity Therapeutics (Alterity Therapeutics) Business Description
Alterity Therapeutics Ltd is active in the healthcare domain. The company is engaged in research collaborations for the treatment of Parkinsonian movement disorders, Alzheimer's disease, Huntington disease, and other neurodegenerative disorders. The company's lead drug candidate-PBT2 is being developed for the treatment of Alzheimer's and Huntington's diseases. It has also advanced a drug candidate for Parkinson's disease and other movement disorders (ATH434). The Group operated in one segment, being researching and developing Parkinsonian and other neurodegenerative disorders.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ATHE has been successfully added to your 